A new genomic test is able to detect with 95% reliability the risk that a person has of developing melanoma, the type of skin cancer more common in Western countries, which has spread, among other causes, as a result of habit -very popular for aesthetic reasons - to sunbathe excessively during leisure time.
At present, around 160,000 new cases of melanoma are diagnosed worldwide each year, a tumor whose appearance could be avoided by taking certain precautions. The new test, in addition to effectively predicting the chances of a person suffering from it, also serves to know the factors that increase the risk of each individual to develop this type of cancer, because although excessive exposure and protection from solar radiation it can cause its appearance, other causes also intervene, including genetic inheritance.
The genomic test that evaluates the possibilities of developing melanoma takes into account environmental, genetic and phenotypic factors to determine the level of risk of each individual
The genomic test takes into account environmental, genetic and phenotypic factors, to determine the level of risk of the individual analyzed, and once the results are known -between 10 and 15 days later-, the specialist can already establish prevention criteria and dermatological checks, as well as sun protection guidelines, both through the application of topical creams, and through the intake of substances that, like antioxidants, have properties to promote skin defenses against melanoma.
This is a breakthrough that will help to improve prevention strategies, since it is early diagnosis and it is not necessary to wait for the appearance of any sign or symptom that reveals the presence of cancer in the initial stages to begin taking measures. In the case of a disease such as melanoma - and because of its propensity to metastasis-, the survival of the patient depends to a large extent on the moment in which it is detected, because while its cure reaches rates of up to 90% when it is diagnosed and treated in the first stages, this percentage decreases up to 10% at five years after diagnosis if it is discovered at an advanced stage.